Polar Capital Holdings PLC Denali Therapeutics Inc. Transaction History

Polar Capital Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $8.98 Million - $12.9 Million	-554,417 Reduced 55.05%	452,669 $9.71 Million
Q2 2023 Dec 13, 2023	BUY	$23.37 - $32.96 $11.7 Million - $16.5 Million	502,086 Added 99.42%	1,007,086 $29.7 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $11.7 Million - $16.5 Million	502,086 Added 99.42%	1,007,086 $29.7 Million
Q1 2023 Dec 13, 2023	SELL	$21.91 - $32.67 $11 Million - $16.4 Million	-502,086 Reduced 49.86%	505,000 $11.6 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $11.1 Million - $16.5 Million	505,000 New	505,000 $11.6 Million
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $1.56 Million - $2.54 Million	-53,835 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.48 - $78.23 $244,193 - $394,044	5,037 Added 10.32%	53,835 $2.72 Million
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $2.45 Million - $3.83 Million	48,798 New	48,798 $3.83 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.